Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTX 130

Next Previous
X
Search
Drug Profile

CTX 130

Alternative Names: CTX-130

Latest Information Update: 15 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CRISPR Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I B-cell lymphoma; Renal cell carcinoma; T-cell lymphoma

Most Recent Events

  • 08 Oct 2024 CRISPR Therapeutics terminates a phase-I clinical trial in Renal cell carcinoma (Second-line therapy or greater, Late-stage disease, Unresectable, Metastatic) in Netherlands, Canada, Australia, USA (IV), as the patients from the trial are to be followed up in the CRSP-ONC-LTF study(NCT04438083)
  • 30 Aug 2024 CRISPR Therapeutics terminates phase I trial in B-cell lymphoma (Second-line therapy or greater) in USA, Australia and Canada (Parenteral) (NCT04502446)
  • 30 Aug 2024 CRISPR Therapeutics terminates phase I trial in T-cell lymphoma (Second-line therapy or greater) in USA, Australia and Canada (Parenteral) (NCT04502446)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top